Calorie Restricted Diet and Urinary Pentosidine in Patients with Rheumatoid Arthritis

Kenichi Iwashige\textsuperscript{1,2), Katsuyasu Kouda\textsuperscript{1,3), Mitsuo Kouda\textsuperscript{4), Kentaro Horiuchi\textsuperscript{5), Masaaki Takahashi\textsuperscript{6), Akira Nagano\textsuperscript{6), Toshiro Tanaka\textsuperscript{7) and Hiroichi Takeuchi\textsuperscript{1)\textsuperscript{1) Department of Public Health, Hamamatsu University School of Medicine\textsuperscript{2) Miyako Clinic\textsuperscript{3) Department of Hygiene, Kansai Medical University\textsuperscript{4) Kouda Clinic\textsuperscript{5) Department of Life Science, Hamamatsu University School of Medicine\textsuperscript{6) Department of Orthopedic Surgery, Hamamatsu University School of Medicine\textsuperscript{7) Third Department of Internal Medicine, School of Medicine, Osaka University

Abstract  Low-energy diets and fasting have suppressive effects on rheumatoid arthritis. It was reported recently that urine levels of pentosidine (i.e., an advanced glycation end product formed by glycosylation) is associated with the activity of rheumatoid arthritis. We conducted a regimen of caloric restriction combined with fasting in patients with rheumatoid arthritis, and then evaluated urinary pentosidine levels. Ten patients with rheumatoid arthritis underwent a 54-day caloric restriction program. Urinary pentosidine levels were measured and the Lansbury Index were determined by examining the clinical features, blood biochemistry and the inflammation activity of rheumatoid arthritis on days 0, 25 and 54. On day 0, the mean urinary pentosidine level of patients with rheumatoid arthritis was significantly higher than that of the control subjects. On day 54, the mean body weight had reduced due to caloric restriction. The mean values of the erythrocyte sedimentation rate and the Lansbury Index of patients both significantly decreased during the study. In addition, although the urinary pentosidine levels showed no significant difference between day 0 and 25, it was significantly decreased at the end of the study (day 54). The study showed that under a low energy diet a reduction of disease activity in rheumatoid arthritis was accompanied with a reduction of the urinary pentosidine. \textit{J Physiol Anthropol Appl Human Sci} 23 (1): 19–24, 2004 http://www.jstage.jst.go.jp/en/

Keywords: caloric restriction, fasting, rheumatoid arthritis, advanced glycation end-product (AGE), pentosidine

Introduction

It is well acknowledged that nutritional stress, such as dietary restriction or fasting, activates various responses. The dietary restriction extends life span and retards the development of chronic diseases (Weindruch and Walford, 1988); it also has beneficial effects on various inflammatory diseases (Fernandes G, 1978; Hishinuma, 1990; Kubo, 1987; Ogura, 1989). Fasting also has suppressive effects on inflammation (Nakamura, 2001); and the immediate consequences of fasting include marked increases in plasma cortisol, ACTH, beta-endorphin, beta-lipotrophic hormone, adrenaline, noradrenaline and dopamine (Becker, 1992; Beer, 1989; Brady, 1990; Komori, 1996).

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease, resulting in the destruction of multiple joints (Firestein GS, 1992; Harris, 1990). Dietary regimens such as fasting, caloric restriction, or a vegetarian diet have the beneficial effects of improving the symptoms of patients with RA (Beri D, 1988; Forre, 1991; Hafström, 1998; Kjeldsen-Kragh J, 1991; Sköldstam et al., 1979; Stroud, 1983; Udén et al., 1983).

It has been reported recently that the serum, urine and synovial fluid levels of pentosidine, correlated with the activities of RA (Chen, 1999; Chen, 1998; Takahashi, 1997). Urinary pentosidine, an advanced glycation end product (AGEs), is a glycoxidation damage biomarker (Chen, 1999; Takahashi, 1997; Takahashi, 1996). The nonenzymatic glycation and oxidation (glycoxidation) reaction of protein is thought to contribute to the cross-linking of tissue proteins, gumming up tissues, making them stiffer and less elastic, and so causing connective tissues to become leathery. In the present study, we conducted a regimen of caloric...
restraint combined with fasting in patients with RA, and evaluated the disease activity by measuring urinary pentosidine levels.

Methods

Subjects

Ten Japanese female patients with RA (age: 58.2±4.8 year; range 48–77) were enrolled in this study. All of them were outpatients of Kouda Clinic located in Osaka. All participants gave informed consent, and the study procedures were in accordance with the Declaration of Helsinki. The patients were diagnosed on the American Rheumatism Association 1987 revised criteria (Arnett, 1988). The mean duration of RA was 6.6 years (range, 1–20). None of the patients had complications of cancers, diabetes mellitus, renal diseases, inflammatory disease or other autoimmune diseases, but one had hypertension.

Six patients took a non-steroidal anti-inflammatory drug (NSAID) and pre-donisolone daily. Their drug therapy had not changed for at least 3 months preceding the study. In five patients, doses of these drugs were diminished according to the degree of improvement in symptoms during the study. None needed an increase in their drugs during the clinical trial.

The control group consisted of 15 healthy females aged 43–80 year (60.2±6.0). They were selected from the group of medical examination in our institution. There was no significant difference in age between RA patients and control subjects. All control subjects had no previous history of diabetes mellitus and renal disease, and were currently receiving no medication.

Trial design and Diet arrangements

Ten RA patients underwent a caloric restricted diet from days 0 to 10, 14 to 24, 31 to 43, and 49 to 54. From day 11 to 13, 25 to 30, and 44 to 48, fasting was conducted (Fig. 1). On a caloric restriction day, the patients were given fresh vegetable juice (corresponding to 250 g of fresh vegetables) at breakfast to avoid any shortage of micronutrients that might accompany dietary restriction. For lunch and dinner, they were given brown rice porridge (corresponding to 80 g of brown rice) sprinkled with 5 g of kelp powder, bean curd (tofu: wet weight 130%, vitamin A 150%, vitamin C 250%, and vitamin E 110% of daily requirements, while was protein 75%, calcium 180%, iron of non-refined salt was also added to the diet. The energy intake (1,085 kcal) was 55% constituted by nutritional requirements, while was protein 75%, calcium 180%, iron 130%, vitamin A 150%, vitamin C 250%, and vitamin E 110% of daily requirements. On a fasting day, only vegetable soup (720 kcal/day) was served.

Collection of serum and urine samples

To measure blood urea nitrogen (BUN), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT), albumin, haemoglobin, erythrocyte sedimentation rate (ESR), and pentosidine, blood and urine samples were collected on the same day from all subjects between 7:00 and 9:00 a.m. on days 0, 25 and 54. For an age-matched control group, 15 healthy volunteers (15 females), aged 35 to 68 years (56.2±2.0) with no history of RA or the known disease also gave urine.

Disease activity in RA

The Lansbury Index (LI) was noted by a rheumatologist on days 0, 25 and 54. LI was determined based on the duration of morning stiffness, erythrocyte sedimentation rate (ESR) (value at 1 hour), grip strength (mmHg) and joint score (Lansbury, 1966; Lansbury, 1957). The joint score was determined as the total sum for painful, tender or swollen joints.

Measurement of urinary pentosidine

The measurement of urinary pentosidine was performed as described (Takahashi, 1993). We identified the pentosidine in a hydrolysate of urine as the total form of pentosidine. After thawing, urine samples were centrifuged at 3000×g for 10 minutes. A 0.5-ml aliquot was hydrolyzed with an equal volume of 12 mol/l hydrochloric acid at 110°C for 17 h in a sealed glass tube. Hydrolysate of urine 0.25-ml was mixed with 15 ml of water and applied to an SP-Sephadex C-25 column (H⁺ form, 0.8×2.0 cm; Pharmacia LKB Biotechnology AB, Uppsala, Sweden) that had been equilibrated with water. The column was washed with 20 ml of 0.15 mol/l hydrochloric acid. The elute evaporated under vacuum, and the residue dissolved in 200 μl of 1% heptafluorobutyric acid. The solutions were stored at −30°C for an analysis.

High-performance liquid chromatography (HPLC)

The HPLC system consisted of a Model LC-6A pump (Shimazu, Kyoto, Japan), a Model 474 spectrofluorometer (Waters Associates, Inc., Milford, MA), a Model AS-8020 autosampler (TOSOH, Tokyo, Japan), and a Model Chromatocorder 12 data processor (SIC, Tokyo, Japan). A column (8 mm×10 cm) prepacked with Radial-Pak C18, of 10-μm particle size, type 8C 1810 μ (Water Associates Inc., Milford, Mass, USA) was used. The flow rate was 1.0 ml/min. The volume of each sample injected was 160 μl. For the detection of pentosidine, the fluorescence at 385 nm was measured on excitation at 335 nm. The level of the pentosidine
content in urine samples is expressed as the micromoles of the pentosidine per 1 mol of urinary creatinine. The urinary creatinine content was measured by a routine method. The standard pentosidine was donated by Dr. V. M. Monnier, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106, U.S.A.

Statistical analysis

Values are expressed mean±standard error. The unpaired t test was used to compare the mean values of urinary pentosidine between the control subjects and RA patients. The paired t test was used to compare the mean values of pentosidine, LI and other variables of RA patients.

Results

None of the participants dropped out of the study. Table 1 shows pathological and laboratory findings. A mean body weight of 2.4 kg of was lost by day 25 of the study, and at the end of the study 4.9 kg (day 54). But, the mean hemoglobin and serum albumin concentrations showed no significant changes during the study. The ESR decreased in 9 patients and the mean ESR showed a significant decrease by day 25 and at day 54 from baseline. There were no statistical differences in serum concentrations of BUN, or liver enzymes such as AST and ALT.

Before caloric restriction (day 0), the mean value of LI was 46.2±7.9%. It decreased significantly during the study: 39.7±6.4% (P<0.05 vs. day 0) on day 25, and 37.6±7.5% (P<0.05 vs. day 0) on day 54 (Fig.2).

The mean value of urinary pentosidine in RA patients was significantly higher than that in control subjects: 4.20±
0.57 \mu mol/mol creatinine vs. 2.04\pm 0.31 \mu mol/mol creatinine (p<0.01) (Fig. 3). In RA patients, there was no significant difference in the urinary pentosidine levels between days 0 and 25 (4.20\pm 0.57 vs. 4.50\pm 0.46 \mu mol/mol creatinine, p = 0.60). However, the urinary pentosidine levels significantly decreased at the end of the study (day 54) compared with the baseline (2.87 \pm 0.36 vs. 4.20\pm 0.52 \mu mol/mol creatinine, P<0.05) (Fig. 4).

Discussion

The pentosidine is one of the advanced glycation endproducts (Monnier, 1992; Sell, 1989; Uchiyama, 1991), and formation of pentosidine was accelerated in the increased sugars concentrations. Accelerated formations of pentosidine in diabetes mellitus (Takahashi, 1993) and in atherosclerotic cardiovascular disease (Uchiyama, 1991) have been reported. Recently, Takahashi et al. (1997) reported that the serum and urine levels of the pentosidine are correlated with the RA activity and then proposed that the serum and urine pentosidine might be a significant novel marker for evaluating RA disease status. In addition, dietary regimens such as fasting, caloric restriction, or vegetarian diet have the beneficial effects by improving symptoms of patients with RA (Beri D, 1988; Hafström, 1998; Kjeldsen-Kragh J, 1991). In the present study, the urine level of pentosidine in patients was significantly higher than that of control females. In addition, we demonstrated a reduction of the pentosidine in patients with RA by caloric restriction, with a simultaneous reduction of the Lansbury Index representing RA disease activity. Furthermore, a reduction of the pentosidine was accompanied by a significant reduction in body weight. This is consistent with previous reports (Kouda et al., 2000; Tanaka et al., 2001). However, the serum albumin, hemoglobin, BUN, AST and ALT were not significantly changed during caloric restriction, although ESR was significantly reduced. These results indicated that a low-energy diet does not malnourish participants, but has a suppressive effect on inflammatory diseases.

The actual mechanism for the reduction of the pentosidine by caloric restriction is unclear. In our study, we combined 3-6 days fasting after the 9–13 days caloric restriction. Previously, it has been hypothesized that the pentosidine formation is accelerated in pathological conditions accompanied with oxidative stress (Kouda et al., 2001; Oya et al., 1997; Suzuki et al., 1999). In animal and clinical studies, the caloric restriction decreases in oxidative damage to tissues (Yu, 1996). The previous reports have demonstrated that the caloric restriction reduces inflammations of dermatitis and the oxidative DNA damage derived from inflammation (Fan et al., 2001; Kouda et al., 2000; Tsuboi et al., 1998). In addition, the caloric restriction results in a decrease in the age-dependent accumulation of glycoxidation products, such as the pentosidine, in tissue (Cefalu et al., 1995; Iqbal et al., 1999; Reiser et al., 1994; Sell et al., 1997; Sell et al., 1996).

Furthermore, the fasting reduces food intolerance (Panush, 1986), diminishes the gastrointestinal permeability (Sundqvist, 1982) and decreases the intake of inflammatory mediators, prostaglandins and leukotrienes (Darlington, 1986). Further, the foodstuffs used in this study were rich in antioxidant. It has been reported that a diet antioxidant and fruites may have an antioxidant effects (Fan WY et al., 2000; Pool-Zobel et al., 1997; Thompson et al., 1999; Verhagen et al., 1997). A complex combination of these mechanisms might relate to the present results.

In conclusion, under a low energy diet the reduction of a RA disease activity was accompanied with a reduction of the urinary pentosidine.

Acknowledgements The authors thank all participants of this study, Dr. Monnier VM (Case Western Reserve University) for the gift of standard pentosidine, Mr. Lin R (Hamamatsu University School of Medicine) and Mr. Yamashima T (Hamamatsu University School of Medicine) for assistance with the measurement of urinary pentosidine.

References


Received: September 8, 2003
Accepted: December 15, 2003
Correspondence and proofs to: Kenichi Iwashige, 312–502, Miyako Clinic Uradeyama-cho, Nakagyo-ku, Kyoto, Kyoto 604–8155, Japan
Phone: +81–75–254–1163
Fax: +81–75–254–1165
e-mail: iwashige@miyako-clinic.jp